Therapeutic Approach to Adult Fibrotic Lung Diseases

Chest

Volumn 150, Issue 6, 2016, Pages 1371-1386

  Adegunsoye, Ayodeji ^a   Strek, Mary E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

connective tissue disease; hypersensitivity pneumonia; idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; interstitial lung disease

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; CARBON MONOXIDE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; IW001; LEBRIKIZUMAB; MYCOPHENOLATE MOFETIL; NANDROLONE; NINTEDANIB; PAMREVLUMAB; PIRFENIDONE; PLACEBO; POMALIDOMIDE; PREDNISONE; PRM 151; RAPAMYCIN; RITUXIMAB; STX 100; TACROLIMUS; TD 139; THALIDOMIDE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ABDOMINAL PAIN; ALLERGIC PNEUMONITIS; ANOREXIA; ANXIETY; BODY WEIGHT DISORDER; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CYTOPENIA; DEATH; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME INHIBITION; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; GLUCOSE INTOLERANCE; HEART INFARCTION; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNE DEFICIENCY; INFECTION; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUNG TRANSPLANTATION; MESENCHYMAL STEM CELL; MYOPATHY; NAUSEA; NEPHROTOXICITY; OSTEOPOROSIS; PHOTOSENSITIVITY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RASH; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SKIN FIBROSIS; SLEEP DISORDERED BREATHING; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SYSTEMIC SCLEROSIS; VOMITING; WEIGHT GAIN; ALVEOLITIS, EXTRINSIC ALLERGIC; CONNECTIVE TISSUE DISEASES; DISEASE COURSE; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL;

ALVEOLITIS, EXTRINSIC ALLERGIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONNECTIVE TISSUE DISEASES; DISEASE PROGRESSION; ENZYME INHIBITORS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; INDOLES; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; PYRIDONES;

EID: 85002649098     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.07.027     Document Type: Review

References (129)

1. 1 King, T.E. Jr., Tooze, J.A., Schwarz, M.I., Brown, K.R., Cherniack, R.M., Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164:7 (2001), 1171–1181.
2. 2 Mooney, J.J., Elicker, B.M., Urbania, T.H., et al. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest 144:2 (2013), 586–592.
3. 3 Kocheril, S.V., Appleton, B.E., Somers, E.C., et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 53:4 (2005), 549–557.
4. 4 Tashkin, D.P., Roth, M.D., Clements, P.J., et al., Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:9 (2016), 708–719.
5. 5 Fernandez Perez, E.R., Daniels, C.E., Schroeder, D.R., et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137:1 (2010), 129–137.
6. 6 Raghu, G., Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J 37:4 (2011), 743–746.
7. 7 Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:6 (2011), 788–824.
8. 8 Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu, G., Anstrom, K.J., King, T.E. Jr., Lasky, J.A., Martinez, F.J., Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366:21 (2012), 1968–1977.
9. 9 Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez, F.J., de Andrade, J.A., Anstrom, K.J., King, T.E. Jr., Raghu, G., Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2093–2101.
10. 10 Grattendick, K.J., Nakashima, J.M., Feng, L., Giri, S.N., Margolin, S.B., Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. Int Immunopharmacol 8:5 (2008), 679–687.
11. 11 Oku, H., Nakazato, H., Horikawa, T., Tsuruta, Y., Suzuki, R., Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 446:1-3 (2002), 167–176.
12. 12 Nakayama, S., Mukae, H., Sakamoto, N., et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 82:3-4 (2008), 210–217.
13. 13 Oku, H., Shimizu, T., Kawabata, T., et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590:1-3 (2008), 400–408.
14. 14 Rubino, C.M., Bhavnani, S.M., Ambrose, P.G., Forrest, A., Loutit, J.S., Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 22:4 (2009), 279–285.
15. 15 Costabel, U., Bendstrup, E., Cottin, V., et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 31:4 (2014), 375–391.
16. 16 Azuma, A., Nukiwa, T., Tsuboi, E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171:9 (2005), 1040–1047.
17. 17 Taniguchi, H., Ebina, M., Kondoh, Y., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respiratory J 35:4 (2010), 821–829.
18. 18 Cottin, V., The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respiratory Res, 14(suppl 1), 2013, S5.
19. 19 Noble, P.W., Albera, C., Bradford, W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:9779 (2011), 1760–1769.
20. 20 Loeh, B., Drakopanagiotakis, F., Bandelli, G.P., et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 191:1 (2015), 110–113.
21. 21 Kreuter, M., Pirfenidone: an update on clinical trial data and insights from everyday practice. Eur Respir Rev 23:131 (2014), 111–117.
22. 22 King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2083–2092.
23. 23 Nathan, S., Albera, C., Bradford, W., et al. Effect of pirfenidone on IPF-related mortality outcome measures in patients with idiopathic pulmonary fibrosis (IPF): pooled data analysis from the ASCEND and CAPACITY trials. Chest., 148(4 suppl), 2015, 391A.
24. 24 Nathan, S.D., Albera, C., Bradford, W.Z., et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 71:5 (2016), 429–435.
25. 25 Behr, J., Bendstrup, E., Crestani, B., et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 4:6 (2016), 445–453.
26. 26 Costabel, U., Albera, C., Bradford, W.Z., et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 31:3 (2014), 198–205.
27. 27 Roth, G.J., Binder, R., Colbatzky, F., et al. Nintedanib: from discovery to the clinic. J Med Chem 58:3 (2015), 1053–1063.
28. 28 Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., Ryffel, B., Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349:2 (2014), 209–220.
29. 29 Kudo, K., Arao, T., Tanaka, K., et al. Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Clin Cancer Res 17:6 (2011), 1373–1381.
30. 30 Hilberg, F., Roth, G.J., Krssak, M., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:12 (2008), 4774–4782.
31. 31 Hostettler, K.E., Zhong, J., Papakonstantinou, E., et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res, 15(1), 2014, 157.
32. 32 Richeldi, L., Costabel, U., Selman, M., et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:12 (2011), 1079–1087.
33. 33 Richeldi, L., Cottin, V., Flaherty, K.R., et al. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 108:7 (2014), 1023–1030.
34. 34 Richeldi, L., du Bois, R.M., Raghu, G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:22 (2014), 2071–2082.
35. 35 Huang, J., Beyer, C., Palumbo-Zerr, K., et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 75:5 (2016), 883–890.
36. 36 Costabel, U., Inoue, Y., Richeldi, L., et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Card Med 193:2 (2016), 178–185.
37. 37 Raghu, G., Rochwerg, B., Zhang, Y., et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Card Med 192:2 (2015), e3–e19.
38. 38 Canestaro, W.J., Forrester, S.H., Raghu, G., Ho, L., Devine, B.E., Drug therapy for treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest 149:3 (2016), 756–766.
39. 39 Wells, A., Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard. Eur Respir J 45:5 (2015), 1208–1210.
40. 40 National Institutes of Health Clinical Center. Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF. NCT02579603. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT02579603. Updated September 5, 2016.
41. 41 Weiss, D.J., Chambers, D., Giangreco, A., et al. An official American Thoracic Society workshop report: stem cells and cell therapies in lung biology and diseases. Ann Am Thorac Soc 12:4 (2015), S79–S97.
42. 42 Toonkel, R.L., Hare, J.M., Matthay, M.A., Glassberg, M.K., Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am J Respir Crit Card Med 188:2 (2013), 133–140.
43. 43 Cardenes, N., Alvarez, D., Corey, C., et al. Deficiencies in mesenchymal stem cells from idiopathic pulmonary fibrosis patients result in lower capacity to protect the lung from injury. Am J Respir Crit Care Med, 193(IC), 2016, A3084.
44. 44 National Institutes of Health Clinical Center. Allogeneic Human Cells (hMSC) in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) (AETHER). NCT02013700. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT02013700. Updated April 13, 2016.
45. 45 Glassberg, M., Toonkel, R.L., Bejarano, P., et al. Safety and tolerability of intravenous bone marrow derived human mesenchymal stem cells for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 193(IC), 2016, A6433.
46. 46 Chambers, D.C., Enever, D., Ilic, N., et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology 19:7 (2014), 1013–1018.
47. 47 Tzouvelekis, A., Paspaliaris, V., Koliakos, G., et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med, 11, 2013, 171.
48. 48 Weiss, D.J., Concise review: current status of stem cells and regenerative medicine in lung biology and diseases. Stem Cells 32:1 (2014), 16–25.
49. 49 Fernandez Perez, E.R., Swigris, J.J., Forssen, A.V., et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 144:5 (2013), 1644–1651.
50. 50 Selman, M., Pardo, A., King, T.E. Jr., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Card Med 186:4 (2012), 314–324.
51. 51 Churg, A., Sin, D.D., Everett, D., Brown, K., Cool, C., Pathologic patterns and survival in chronic hypersensitivity pneumonitis. Am J Surg Pathol 33:12 (2009), 1765–1770.
52. 52 Morell, F., Villar, A., Montero, M.A., et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 1:9 (2013), 685–694.
53. 53 Garcia de Alba, C., Buendia-Roldan, I., Salgado, A., et al. Fibrocytes contribute to inflammation and fibrosis in chronic hypersensitivity pneumonitis through paracrine effects. Am J Respir Crit Card Med 191:4 (2015), 427–436.
54. 54 Lima, M.S., Coletta, E.N., Ferreira, R.G., et al. Subacute and chronic hypersensitivity pneumonitis: histopathological patterns and survival. Respir Med 103:4 (2009), 508–515.
55. 55 Gaxiola, M., Buendia-Roldan, I., Mejia, M., et al. Morphologic diversity of chronic pigeon breeder's disease: clinical features and survival. Respir Med 105:4 (2011), 608–614.
56. 56 Chiba, S., Tsuchiya, K., Akashi, T., et al. Chronic hypersensitivity pneumonitis with a usual interstitial pneumonia-like pattern: correlation between histopathological and clinical findings. Chest 149:6 (2016), 1473–1481.
57. 57 Ryerson, C.J., Vittinghoff, E., Ley, B., et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 145:4 (2014), 723–728.
58. 58 Adegunsoye, A., Oldham, J.M., Demchuk, C., Montner, S., Vij, R., Strek, M.E., Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respir Med 114 (2016), 53–60.
59. 59 Kokkarinen, J.I., Tukiainen, H.O., Terho, E.O., Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis 145:1 (1992), 3–5.
60. 60 Keir, G.J., Maher, T.M., Ming, D., et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:3 (2014), 353–359.
61. 61 Kern, R.M., Singer, J.P., Koth, L., et al. Lung transplantation for hypersensitivity pneumonitis. Chest 147:6 (2015), 1558–1565.
62. 62 Vij, R., Strek, M.E., Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 143:3 (2013), 814–824.
63. 63 Hu, Y., Wang, L.S., Wei, Y.R., et al. Clinical characteristics of connective tissue disease-associated interstitial lung disease in 1,044 Chinese patients. Chest 149:1 (2016), 201–208.
64. 64 Fischer, A., Antoniou, K.M., Brown, K.K., et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 46:4 (2015), 976–987.
65. 65 Khanna, D., Mittoo, S., Aggarwal, R., et al. Connective tissue disease-associated interstitial lung diseases (CTD-ILD)—report from OMERACT CTD-ILD Working Group. J Rheumatol 42:11 (2015), 2168–2171.
66. 66 Goldin, J.G., Lynch, D.A., Strollo, D.C., et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 134:2 (2008), 358–367.
67. 67 Goh, N.S., Desai, S.R., Veeraraghavan, S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Card Med 177:11 (2008), 1248–1254.
68. 68 Tashkin, D.P., Elashoff, R., Clements, P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:25 (2006), 2655–2666.
69. 69 Hoyles, R.K., Ellis, R.W., Wellsbury, J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:12 (2006), 3962–3970.
70. 70 Tashkin, D.P., Elashoff, R., Clements, P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Card Med 176:10 (2007), 1026–1034.
71. 71 Tashkin, D., Roth, M., Clements, P., et al. Efficacy and safety of mycophenolate (MMF) vs oral cyclophosphamide (CYC) for treatment of scleroderma-interstitial lung disease (Ssc-ILD): results of Scleroderma Lung Study II. Chest, 148(4 suppl), 2015, 637A.
72. 72 National Institutes of Health Clinical Center. Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis–Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) (LOTUSS). NCT01933334. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT01933334. Updated July 6, 2016.
73. 73 Khanna, D., Albera, C., Fischer, A., et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol 43:9 (2016), 1672–1679.
74. 74 Khanna, D., Albera, C., Fischer, A., et al. Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)—the LOTUSS study. Eur Respir J, 46(suppl 59), 2015, OA4489.
75. 75 Steen, V.D., Medsger, T.A. Jr., Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41:9 (1998), 1613–1619.
76. 76 Jordan, S., Distler, J.H., Maurer, B., et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:6 (2015), 1188–1194.
77. 77 National Institutes of Health Clinical Center. A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis. NCT02597933. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT02597933. Updated September 5, 2016.
78. 78 Karjigi, U., Gordon, J., Palmer, E., et al. Cyclophosphamide in the treatment of severe interstitial lung disease in patients with rheumatoid arthritis. Rheumatology (2015), 54(suppl 1), 2015, i77.
79. 79 Chartrand, S., Fischer, A., Management of connective tissue disease-associated interstitial lung disease. Rheum Dis Clin North Am 41:2 (2015), 279–294.
80. 80 National Institutes of Health Clinical Center. NCT02808871.
81. 81 Mira-Avendano, I.C., Parambil, J.G., Yadav, R., et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 107:6 (2013), 890–896.
82. 82 Fischer, A., Brown, K.K., Du Bois, R.M., et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40:5 (2013), 640–646.
83. 83 Cavagna, L., Caporali, R., Abdi-Ali, L., Dore, R., Meloni, F., Montecucco, C., Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol 40:4 (2013), 484–492.
84. 84 Labirua-Iturburu, A., Selva-O'Callaghan, A., Martinez-Gomez, X., Trallero-Araguas, E., Labrador-Horrillo, M., Vilardell-Tarres, M., Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 31:3 (2013), 436–439.
85. 85 Witt, L.J., Demchuck, C., Curran, J.J., Strek, M.E., Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther 36 (2016), 46–52.
86. 86 Solomon, J.J., Olson, A.L., Fischer, A., Bull, T., Brown, K.K., Raghu, G., Scleroderma lung disease. Eur Respir Rev 22:127 (2013), 6–19.
87. 87 Baughman, R.P., Meyer, K.C., Nathanson, I., et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 142:5 (2012), e1S–e111.
88. 88 Vananuvat, P., Suwannalai, P., Sungkanuparph, S., Limsuwan, T., Ngamjanyaporn, P., Janwityanujit, S., Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 41:3 (2011), 497–502.
89. 89 Grossman, J.M., Gordon, R., Ranganath, V.K., et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:11 (2010), 1515–1526.
90. 90 King, C., Nathan, S.D., Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med 19:5 (2013), 466–473.
91. 91 Schmidt, S.L., Nambiar, A.M., Tayob, N., et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38:1 (2011), 176–183.
92. 92 Cottin, V., Nunes, H., Mouthon, L., et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 63:1 (2011), 295–304.
93. 93 Fujimoto, D., Tomii, K., Otoshi, T., et al. Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. Lung Cancer 80:2 (2013), 159–164.
94. 94 Hubbard, R., Venn, A., Lewis, S., Britton, J., Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 161:1 (2000), 5–8.
95. 95 Tomassetti, S., Gurioli, C., Ryu, J.H., et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 147:1 (2015), 157–164.
96. 96 Sprunger, D.B., Olson, A.L., Huie, T.J., et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 39:1 (2012), 125–132.
97. 97 Luo, Q., Xie, J., Han, Q., et al. Prevalence of venous thromboembolic events and diagnostic performance of the Wells score and revised Geneva scores for pulmonary embolism in patients with interstitial lung disease: a prospective study. Heart Lung Circ 23:8 (2014), 778–785.
98. 98 Dalleywater, W., Powell, H.A., Hubbard, R.B., Navaratnam, V., Risk factors for cardiovascular disease in people with idiopathic pulmonary fibrosis: a population-based study. Chest 147:1 (2015), 150–156.
99. 99 Nathan, S.D., Basavaraj, A., Reichner, C., et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 104:7 (2010), 1035–1041.
100. 100 Koduri, G., Norton, S., Young, A., et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology 49:8 (2010), 1483–1489.
101. 101 Akhtar, A.A., Ali, M.A., Smith, R.P., Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis 10:3 (2013), 127–133.
102. 102 Holland, A.E., Fiore, J.F. Jr., Bell, E.C., et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology 19:8 (2014), 1215–1221.
103. 103 Ryerson, C.J., Cayou, C., Topp, F., et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med 108:1 (2014), 203–210.
104. 104 Nathan, J., Fuld, J., Skeletal muscle dysfunction: a ubiquitous outcome in chronic disease?. Thorax 65:2 (2010), 97–98.
105. 105 Paffenbarger, R.S. Jr., Hyde, R.T., Wing, A.L., Hsieh, C.C., Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med 314:10 (1986), 605–613.
106. 106 Vainshelboim, B., Oliveira, J., Yehoshua, L., et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration 88:5 (2014), 378–388.
107. 107 Jackson, R.M., Gomez-Marin, O.W., Ramos, C.F., et al. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung 192:3 (2014), 367–376.
108. 108 Savarino, E., Carbone, R., Marabotto, E., et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J 42:5 (2013), 1322–1331.
109. 109 Savarino, E., Bazzica, M., Zentilin, P., et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 179:5 (2009), 408–413.
110. 110 Lee, J.S., Ryu, J.H., Elicker, B.M., et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:12 (2011), 1390–1394.
111. 111 Kreuter, M., Wuyts, W., Renzoni, E., et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 4:5 (2016), 381–389.
112. 112 Barletta, J.F., El-Ibiary, S.Y., Davis, L.E., Nguyen, B., Raney, C.R., Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clinic Proc 88:10 (2013), 1085–1090.
113. 113 Seto, C.T., Jeraldo, P., Orenstein, R., Chia, N., DiBaise, J.K., Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome, 2, 2014, 42.
114. 114 Shah, N.H., LePendu, P., Bauer-Mehren, A., et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PloS One, 10(6), 2015, e0124653.
115. 115 Lazarus, B., Chen, Y., Wilson, F.P., et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176:2 (2016), 238–246.
116. 116 National Institutes of Health Clinical Center. Microaspiration in Pulmonary Fibrosis (ROMI). NCT01150591. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT01150591. Updated December 1, 2015.
117. 117 National Institutes of Health Clinical Center. Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough. NCT01667042. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT01667042. Updated January 7, 2016.
118. 118 National Institutes of Health Clinical Center. The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis. NCT02136394. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT02136394. Updated April 6, 2016.
119. 119 National Institutes of Health Clinical Center. Treatment of IPF With Laparoscopic Anti-Reflux Surgery (WRAP-IPF). NCT01982968. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT01982968. Updated December 1, 2015.
120. 120 Lancaster, L.H., Mason, W.R., Parnell, J.A., et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 136:3 (2009), 772–778.
121. 121 Pihtili, A., Bingol, Z., Kiyan, E., Cuhadaroglu, C., Issever, H., Gulbaran, Z., Obstructive sleep apnea is common in patients with interstitial lung disease. Sleep Breath 17:4 (2013), 1281–1288.
122. 122 Mermigkis, C., Bouloukaki, I., Antoniou, K., et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath 19:1 (2015), 385–391.
123. 123 Shorr, A.F., Wainright, J.L., Cors, C.S., Lettieri, C.J., Nathan, S.D., Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 30:4 (2007), 715–721.
124. 124 Zisman, D.A., Karlamangla, A.S., Kawut, S.M., et al. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 133:3 (2008), 640–645.
125. 125 Papakosta, D., Pitsiou, G., Daniil, Z., et al. Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters. Lung 189:5 (2011), 391–399.
126. 126 Raghu, G., Behr, J., Brown, K.K., et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 158:9 (2013), 641–649.
127. 127 National Institutes of Health Clinical Center. Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (RISE-IIP). NCT02138825. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT02138825. Updated June 13, 2016.
128. 128 Kistler, K.D., Nalysnyk, L., Rotella, P., Esser, D., Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med, 14, 2014, 139.
129. 129 National Institutes of Health Clinical Center. European Trial of Pirfenidone in BOS, A European Multi-center Study (EPOS). NCT02262299. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2007. https://clinicaltrials.gov/ct2/show/NCT02262299. Updated November 3, 2015.